drugset / Trial / NCT06273215

Evaluation of the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Diabetic Patients

NCT06273215 ↗

Phase 4 Unknown 48 enrolled Peking University Third Hospital
Non-randomizedParallel-groupOpen-labelBasic science

Summary

1.To explore the functional changes of P-gp, CYP3A4, OATP1B and BCRP in Diabetic patients (including the non-obese T2DM, obese T2DM, elderly T2DM, and T1DM).

Timeline

Start
2023-03-05
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 100 ug —
Subject Dabigatran etexilate Unknown 375 ug —
Subject Midazolam Small molecule 10 ug —
Subject Pitavastatin Small molecule 10 ug —
Subject Rosuvastatin Small molecule 50 ug —

Indications